MENU
+Compare
ABUS
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$3.13
Change
-$0.07 (-2.19%)
Capitalization
599.48M

ABUS Arbutus Biopharma Corp Forecast, Technical & Fundamental Analysis

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases... Show more

Industry: #Biotechnology
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ABUS with price predictions
Jun 27, 2025

ABUS's RSI Oscillator stoops into oversold zone

The RSI Oscillator for ABUS moved into overbought territory on June 27, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for ABUS crossed bullishly above the 50-day moving average on June 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .

ABUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 220 cases where ABUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ABUS as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ABUS turned negative on June 20, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

ABUS moved below its 50-day moving average on June 25, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ABUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.576) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). ABUS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (92.593) is also within normal values, averaging (252.247).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ABUS is expected to report earnings to fall 66.15% to -4 cents per share on July 31

Arbutus Biopharma Corp ABUS Stock Earnings Reports
Q2'25
Est.
$-0.04
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.02
Q3'24
Missed
by $0.01
Q2'24
Missed
by $0.01
The last earnings report on May 14 showed earnings per share of -12 cents, missing the estimate of -10 cents. With 1.84M shares outstanding, the current market capitalization sits at 599.48M.
A.I. Advisor
published General Information

General Information

a developer of drugs to improve the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
701 Veterans Circle
Phone
+1 267 469-0914
Employees
73
Web
http://www.arbutusbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYRAX50.260.53
+1.07%
Rydex Retailing H
HGOFX69.830.59
+0.85%
Hartford Growth Opportunities F
IRLSX75.670.50
+0.67%
Voya Russell Large Cap Growth Idx Port S
GCVIX23.900.03
+0.13%
Goldman Sachs Large Cp Val Insghts Instl
VSFRX22.97N/A
N/A
Federated Hermes Clover Small Value R

ABUS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-2.19%
IDYA - ABUS
46%
Loosely correlated
-4.13%
DNLI - ABUS
43%
Loosely correlated
-2.69%
IMVT - ABUS
43%
Loosely correlated
-1.77%
KRYS - ABUS
42%
Loosely correlated
-2.60%
TERN - ABUS
42%
Loosely correlated
-4.25%
More